Notification of Admission of Shares and TVR
Solvonis Therapeutics PLC
30 September 2026
Solvonis Therapeutics plc
("Solvonis" or the "Company")
Notification of Admission of Shares and TVR
LONDON - 30 September 2026 - Solvonis Therapeutics plc (LSE: SVNS), a late clinical-stage biopharmaceutical company developing novel small-molecule therapeutics for high-burden central nervous system ("CNS") disorders, announces that further to the Company's announcement on 25 August 2026 regarding the allotment and admission of new Ordinary shares, provides the following additional information in accordance with the Public Offers and Admissions to Trading Regulations 2024 (POATRs) PRM 1.6.4R.
|
1 |
Details of the issuer |
|
|
a) |
Name |
Solvonis Therapeutics plc |
|
b) |
LEI |
2138005PH7OJRCRPUD88 |
|
2 |
Details of the transferable securities admitted to trading |
|
|
a) |
Name, type and identification code |
Ordinary Shares; ISIN: GB00BMD1Z199 |
|
b) |
Regulated market |
London Stock Exchange - Main Market |
|
c) |
Number of further securities admitted |
1,093,333,333 ordinary shares |
|
d) |
Total number of securities in issue following admission |
7,899,736,826 |
|
e) |
Fungibility |
Fully fungible with existing Ordinary Shares |
|
3 |
Admission details |
|
|
a) |
Date of admission |
28th August 2026 |
|
b) |
Prospectus information |
Prospectus: N/A Supplementary: N/A Company's website: https://solvonis.com/ |
|
c) |
Coverage of notification |
All admissions up to and including 28th August 2026 |
Total Voting Rights
In accordance with the Financial Conduct Authority's ("FCA") Disclosure and Transparency Rules, the Company hereby announces that as at 30 September 2026 there were 7,899,736,826 ordinary shares of £0.001 each in issue, none of which are held in treasury. Therefore, the total number of voting rights in the Company is 7,899,736,826.
The above figure of 7,899,736,826 may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FCA's Disclosure and Transparency Rules.
The Directors of the Company are responsible for the release of this announcement.
Enquiries
Solvonis Therapeutics plc
Anthony Tennyson, Chief Executive Officer and Executive Director
info@solvonis.com
Turner Pope Investments (TPI) Limited
Corporate Broker and Sole Bookrunner
Andrew Thacker / Guy McDougall
+44 (0)20 3657 0050
About Solvonis Therapeutics plc
Solvonis Therapeutics plc (LSE: SVNS) is a late clinical-stage biopharmaceutical company developing small-molecule therapeutics for high-burden central nervous system ("CNS") disorders. Headquartered in London and listed on the Main Market of the London Stock Exchange, Solvonis is advancing a differentiated pipeline of repurposed and discovery-stage compounds across addiction and psychiatry.
The Company's lead programmes target Alcohol Use Disorder ("AUD") and Post-Traumatic Stress Disorder ("PTSD"), with additional development and discovery work supporting expansion into further addiction and psychiatric indications, including stimulant use disorder and depressive disorders.
Its lead asset, SVN-001, is currently in Phase 3 for severe AUD in the UK, while SVN-002 is being advanced towards a planned Phase 2b trial in the United States targeting moderate-to-severe AUD. The Company's PTSD discovery programme has identified SVN-114 as a lead compound, emerging from a proprietary compound series designed to modulate key brain-signalling systems associated with emotional processing and social behaviour.
SVN-015 is the Company's proprietary discovery-stage candidate targeting stimulant use disorder. Following encouraging initial cardiac ion-channel and broader off-target screening results, it is advancing into further preclinical evaluation under NIDA's Addiction Treatment Discovery Program.
In parallel, Solvonis is advancing proprietary CNS discovery programmes supported by a dedicated compound library and AI-enabled discovery capabilities to identify new small-molecule modulators of key neurotransmitter systems.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
ENDRNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.